2009 : Minakem acquires the AstraZeneca's state-of-the-art API site in Dunkirk, which allows to expand by an extra 150m3 reactor capacity, micronization and injectabe capabilities 2005 : Minakem Holding SAS acquired all the assets related to the custom synthesis, including the R&D laboratories, pilot plant and manufacturing resources from SEAC. Operating under the name of Minakem SAS, headquarters were rel...